Angene Chemical
Draw
|
Currency :
Home Products

AG0034IQ

439081-18-2 | N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide

Chemical structure of N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide, CAS 439081-18-2
AG0034IQ
sdsSDS
sdsCOA

Price

$0.00

Add to Cart
WARNING This product is not for human or veterinary use.
Request For Quotation
CAS Number 439081-18-2
Catalog Number AG0034IQ(AGN-PC-0RS25N)
Chemical Name N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
EC Number 923-981-5
IUPAC Name (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
InChI InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1
InChI Key ULXXDDBFHOBEHA-CWDCEQMOSA-N
MDL Number MFCD12407405
Molecular Formula C24H25ClFN5O3
Molecular Weight 485.9384
NSC Number 750691
SMILES ClC=1C=C(C=CC1F)NC1=NC=NC2=CC(=C(C=C12)NC(C=CCN(C)C)=O)O[C@@H]1COCC1
UNII 41UD74L59M
Synonyms
(2E)-N-(4-(3-chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide, afatinib, afatinib dimaleate, afatinib maleate, BIBW 2992, BIBW 2992 MA2, BIBW 2992MA2, BIBW-2992, BIBW-2992-MA2, BIBW-2992MA2, BIBW2992, BIBW2992 MA2, Gilotrif, Afatinib, 439081-18-2, 850140-72-6, BIBW2992, Tovok, BIBW 2992, Tomtovok, BIBW-2992, Afatinib (BIBW2992), (S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide, afatinibum, UNII-41UD74L59M, Tovok,BIBW2992, (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide, (S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-Butenamide, CHEMBL1173655, CHEBI:61390, 41UD74L59M, S1011, (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide, (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide, J-500781, J-502300, (2e)-n-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3s)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-2-butenamide, 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-, C24H25ClFN5O3, Afatinib [USAN:INN], (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl)-amide, (E)-4-Dimethylamino-but-2-enoic acid-[4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6-yl]-amide, 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-, (2E)-, Afatinib Impurity G, Afatinib, Free Base, BIBW2992,Afatinib, PubChem22403, Afatinib (USAN/INN), BIBW2992 - Afatinib, Tovok|||BIBW 2992, (2E)-N-(4-(3-chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide, MLS006010000, BIFK0010, GTPL5667, CHEBI:94698, EX-A065, QCR-169, ULXXDDBFHOBEHA-CWDCEQMOSA-N, ZX-AFC000305, BCPP000338, (R,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide, AMX10177, AOB87785, BCP01779, ZINC3976838, BIBW2992/Tovok,BIBW-2992, 3123AC, ABP000859, AN-537, BDBM50322823, MFCD12407405, NSC750691, Afatinib(cis-trans isomerismtautomers), AKOS015850681, AKOS015904219, AKOS025149636, BCP9000407, DB08916, EX-8656, NSC-750691, PB28439, RL05240, NCGC00185000-01, AC-26079, AC-27018, AJ-47553, AM808098, DS-14172, SC-66830, SC-87772, SMR004701084, AB0033685, AX8164181, AX8210970, TC-162525, TC-163608, FT-0083487, ST24036355, SW219248-1, X7366, A15572, D09724, Q-3651, AB01565886_02, 081B182, SR-01000941576, SR-01000941576-1, 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino, BRD-K66175015-001-01-7, I14-17009, (2E)-N-[4-(3-Chloro-4-fluoroanilino)-7-[[(3S)-oxolane-3-yl]oxy]quinazoline-6-yl]-4-(dimethylamino)-2-buteneamide, (E)-4-dimethylamino-but-2-enoic acid-(4-(3-chloro-4-fluoro-phenylamino)-7-((S)-tetrahydrofuran-3-yloxy)-quinazolin-6yl)-amide, (E)-N-[4-(3-chloro-4-fluoro-anilino)-7-[(3S)-tetrahydrofuran-3-yl]oxy-quinazolin-6-yl]-4-(dimethylamino)but-2-enamide, (S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide, N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3''S'')-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide, Gilotrif, Afatinib maleate, Afatinib [USAN], Tovok (TN), AFATINIB DIMALEATE, BIBW2992 Afatinib, Tovok, BIBW2992, EGFR inhibitor 2nd gens, D05UFG, cc-109, BIBW 2992MA2, BIBW-2992MA2, BIBW2992 MA2, BIBW 2992 MA2, BIBW-2992-MA2, Afatinib, 99% - 25MG 25mg, ACN-036294, CS-T-01429, CID10184653, CID 10184653, PD0332991, A8247, A10141, C522924, D000077716, 0WM, 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)- 6-quinazolinyl)-4-(dimethylamino)-, (2E)-, 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, 2-butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2e)-, (2Z)-2-butenedioate (1:2), 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one 2-hydroxy-ethanesulfonic acid (1:1),

Related Research Chemicals

    CERTIFICATE OF ANALYSIS
    Chemical Name: Batch Number:
    Chemical Structure: CAS Registry No:
    		Product ID:
    Manufacture Date:
    Storage Temperature:
    Formula:
    Molecular Weight:
    Quantity:
    Analysis Data:
    Test: Result:
    Conclusion: The above product meets the specifications of Angene.
    Analyst:Chase
    Date:
    Reviewed by:Jessie
    Date:
    Angene International Limited